 Receptors, Growth Factor
"Receptors, Growth Factor" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Cell surface receptors that bind growth or trophic factors with high affinity, triggering intracellular responses which influence the growth, differentiation, or survival of cells.
| Descriptor ID |
D017978
|
| MeSH Number(s) |
D12.776.543.750.750.400
|
| Concept/Terms |
Receptors, Growth Factor- Receptors, Growth Factor
- Receptors, Growth Factors
- Growth Factors Receptors
- Growth Factor Receptors
Trophic Factor Receptors- Trophic Factor Receptors
- Receptors, Trophic Factor
- Trophic Factor Receptor
- Factor Receptor, Trophic
- Receptor, Trophic Factor
|
Below are MeSH descriptors whose meaning is more general than "Receptors, Growth Factor".
Below are MeSH descriptors whose meaning is more specific than "Receptors, Growth Factor".
- Receptors, Growth Factor
- Bone Morphogenetic Protein Receptors
- Proto-Oncogene Proteins c-met
- Receptor, Epidermal Growth Factor
- Receptor, erbB-2
- Receptor, erbB-3
- Receptors, Colony-Stimulating Factor
- Receptors, Fibroblast Growth Factor
- Receptors, Nerve Growth Factor
- Receptors, Platelet-Derived Growth Factor
- Receptors, Somatomedin
- Receptors, Transforming Growth Factor beta
- Receptors, Vascular Endothelial Growth Factor
This graph shows the total number of publications written about "Receptors, Growth Factor" by people in this website by year, and whether "Receptors, Growth Factor" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 1 | 0 | 1 | | 1996 | 0 | 1 | 1 | | 1997 | 0 | 1 | 1 | | 1998 | 0 | 1 | 1 | | 1999 | 0 | 2 | 2 | | 2000 | 1 | 1 | 2 | | 2001 | 1 | 0 | 1 | | 2002 | 0 | 1 | 1 | | 2005 | 0 | 1 | 1 | | 2008 | 1 | 1 | 2 | | 2009 | 3 | 0 | 3 | | 2010 | 1 | 3 | 4 | | 2011 | 2 | 3 | 5 |
To return to the timeline, click here.
Below are the most recent publications written about "Receptors, Growth Factor" by people in Profiles.
-
Catenacci DV, Cervantes G, Yala S, Nelson EA, El-Hashani E, Kanteti R, El Dinali M, Hasina R, Brägelmann J, Seiwert T, Sanicola M, Henderson L, Grushko TA, Olopade O, Karrison T, Bang YJ, Kim WH, Tretiakova M, Vokes E, Frank DA, Kindler HL, Huet H, Salgia R. RON (MST1R) is a novel prognostic marker and therapeutic target for gastroesophageal adenocarcinoma. Cancer Biol Ther. 2011 Jul 01; 12(1):9-46.
-
Stoddart A, Tennant TR, Fernald AA, Anastasi J, Brodsky FM, Le Beau MM. The clathrin-binding domain of CALM-AF10 alters the phenotype of myeloid neoplasms in mice. Oncogene. 2012 Jan 26; 31(4):494-506.
-
Ou SH, Kwak EL, Siwak-Tapp C, Dy J, Bergethon K, Clark JW, Camidge DR, Solomon BJ, Maki RG, Bang YJ, Kim DW, Christensen J, Tan W, Wilner KD, Salgia R, Iafrate AJ. Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification. J Thorac Oncol. 2011 May; 6(5):942-6.
-
Salgia R, Hensing T, Campbell N, Salama AK, Maitland M, Hoffman P, Villaflor V, Vokes EE. Personalized treatment of lung cancer. Semin Oncol. 2011 Apr; 38(2):274-83.
-
Jensen AR, David SY, Liao C, Dai J, Keller ET, Al-Ahmadie H, Dakin-Haché K, Usatyuk P, Sievert MF, Paner GP, Yala S, Cervantes GM, Natarajan V, Salgia R, Posadas EM. Fyn is downstream of the HGF/MET signaling axis and affects cellular shape and tropism in PC3 cells. Clin Cancer Res. 2011 May 15; 17(10):3112-22.
-
Ou SH, Bazhenova L, Camidge DR, Solomon BJ, Herman J, Kain T, Bang YJ, Kwak EL, Shaw AT, Salgia R, Maki RG, Clark JW, Wilner KD, Iafrate AJ. Rapid and dramatic radiographic and clinical response to an ALK inhibitor (crizotinib, PF02341066) in an ALK translocation-positive patient with non-small cell lung cancer. J Thorac Oncol. 2010 Dec; 5(12):2044-6.
-
Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, Maki RG, Ou SH, Dezube BJ, Jänne PA, Costa DB, Varella-Garcia M, Kim WH, Lynch TJ, Fidias P, Stubbs H, Engelman JA, Sequist LV, Tan W, Gandhi L, Mino-Kenudson M, Wei GC, Shreeve SM, Ratain MJ, Settleman J, Christensen JG, Haber DA, Wilner K, Salgia R, Shapiro GI, Clark JW, Iafrate AJ. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med. 2010 Oct 28; 363(18):1693-703.
-
Maselli RA, Arredondo J, Cagney O, Ng JJ, Anderson JA, Williams C, Gerke BJ, Soliven B, Wollmann RL. Mutations in MUSK causing congenital myasthenic syndrome impair MuSK-Dok-7 interaction. Hum Mol Genet. 2010 Jun 15; 19(12):2370-9.
-
Tan YH, Krishnaswamy S, Nandi S, Kanteti R, Vora S, Onel K, Hasina R, Lo FY, El-Hashani E, Cervantes G, Robinson M, Hsu HS, Kales SC, Lipkowitz S, Karrison T, Sattler M, Vokes EE, Wang YC, Salgia R. CBL is frequently altered in lung cancers: its relationship to mutations in MET and EGFR tyrosine kinases. PLoS One. 2010 Jan 29; 5(1):e8972.
-
Mascarenhas JB, Young KP, Littlejohn EL, Yoo BK, Salgia R, Lang D. PAX6 is expressed in pancreatic cancer and actively participates in cancer progression through activation of the MET tyrosine kinase receptor gene. J Biol Chem. 2009 Oct 02; 284(40):27524-32.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|